A Phase 1/2 Open-label Clinical Study to Evaluate the Safety and Efficacy of Intravesical Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Participants With Intermediate-risk Nonmuscle Invasive Bladder Cancer (NMIBC)
Latest Information Update: 17 Oct 2024
At a glance
- Drugs Sacituzumab Tirumotecan (Primary)
- Indications Bladder cancer
- Focus Adverse reactions
- Acronyms TroFuse-027
- Sponsors Merck Sharp & Dohme
- 17 Oct 2024 New trial record